Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1507-1515

  Schneider, Joachim ^a   Bitterlich, Norman ^b   Schulze, Guntram ^c  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Medttin und Service   (Germany)

^c Institut für Labordiagnostik   (Germany)

Author keywords

Fuzzy logic; Gastro intestinal cancer; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ONCOPROTEIN; PROTEIN M2; PYRUVATE KINASE; TUMOR MARKER;

ADULT; AGED; ANALYTIC METHOD; CANCER DIAGNOSIS; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MODEL; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; STOMACH CANCER;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FUZZY LOGIC; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PYRUVATE KINASE; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 21244501795     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Keller T, Bitterlich N, Hilfenhaus S, Bigl H, Löser T and Leonhardt P: Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profiles. J Cancer Res Clin Oncol 124: 565-574, 1998.
2. Schneider, J, Bitterlich N, Velcovsky HG, Morr H, Katz N and Eigenbrodt E: Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol 7: 145-151, 2002.
3. Eigenbrodt E, Baseanu D, Holthusen S, Mazurek S and Fischer G: Quantification of tumor type M2 pyruvate kinase (TuM2-PK) in human carcinomas. Anticancer Res 17: 3153-3156, 1997.
4. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H and Klör HU: Tumor M2-PK: A promising tumor marker in the diagnosis of gastrointestinal cancer. Anticancer Res 20: 4965-4968, 2002.
5. Lüftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD and Possinger K: Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 20: 5077-5082, 2000.
6. Schneider J, Morr H, Velcovsky HG, Weisse G and Eigenbrodt E: Quantitative detection of Tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prevent 24: 531-535, 2000.
7. Schneider J, Velcovsky HG, Morr H, Katz N, Neu K and Eigenbrodt E: Comparison of the tumor markers Tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 20: 5053-5058, 2000.
8. Schulze G: The tumor marker Tumor M2-PK: An application in the diagnosis of gastrointestinal cancer. Anticancer Res 20: 4961-4964, 2000.
9. Wechsel HW, Feil G, Lahme S, Loeser W and Bichler KH: Plasma-inactive form of pyruvate kinase (pTuM2PK) in renal cell carcinoma (RCC): an acceptable marker? Akt Urol 30: 249-253, 1999.
10. 2 (Tumor M2-PK). Anticancer Res 19: 2583-2590, 1999.
11. Zadeh LA: Fuzzy sets. Inform Control 8: 35-40, 1965.
12. Zimmermann HJ: Fuzzy Set Theory and Its Application, 2nd edn. Kluwer, Boston, 1991.
13. Bocklisch SF and Bitterlich N: Fuzzy pattern classification-methodology and application. In: Kruse R, Gebhard J, Palm R (eds): Fuzzy Systems in Computer Science. Vieweg, Wiesbaden, 1994.
14. Cruz GPA and Beliakov G: Fuzzy gating and the problem of screening. Artif Intell Med 8: 377-385, 1996.
15. Heptner G, Domschke S and Domschke W: Comparison of CA72-4 with CA19-9 and carcinoembryonic antigen in the serodiagnosis of gastrointestinal maligancies. Scand J Gastroenterol 24: 745-750, 1989.
16. Kodama I, Koufuji K, Kabata S, Tetsu S, Tsuji Y, Takeda J and Kakegawa T: The clinical efficacy of CA72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA. Int Surg 80: 45-48, 1995.
17. Lai IR, Lee WJ, Huang MT and Lin HH: Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA 125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 49: 1157-1160, 2002.
18. Ohuchi N, Takahashi K, Matoba N, Sato T, Taira Y, Sakai N, Masuda M and Mori S: Comparison of serum assays for TAG-72, CA19-9 and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol 19: 242-248, 1989.
19. Stieber P, Fateh-Moghadam A, Wädlich H, Nagel D, Lamerz R and Denecke D: A new tumor marker for stomach cancer. In: Klapdor R (ed): Recent Results in Tumor Diagnosis and Therapy. München, Zuckschwedt, pp. 23-26, 1990.
20. Ychou M, Duffour J, Kramar A, Goergoe S and Grenier J: Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers 16: 105-110, 2000.
21. Lombardi C, Tassi GF, Pizzocolo G and Donato F: Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis. Chest 97: 639-644, 1990.
22. Gail MH, Muenz L, Mclntire KR, Radovich B, Braunstein G, Brown PR, Deftos L, Dnistrian A, Dunsmore M, Elashoff R, Geller N, Go VLW, Hirji K, Klauber MR, Pee D, Petroni G, Schwartz M and Wolfsen AR: Multiple markers for lung cancer diagnosis: validation of models for advanced lung cancer. J Nat Cancer Inst 76: 805-816, 1986.
23. Gail MH, Muenz L, McIntire KR, Radovich B, Braunstein G, Brown PR, Deftos L, Dnistrian A, Dunsmore M, Elashoff R, Geller N, Go VLW, Hirji K, Klauber MR, Pee D, Petroni G, Schwartz M and Wolfsen AR: Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer. J Nat Cancer Inst 80: 97-101, 1988.